Omega Therapeutics Investor Relations Material

Omega Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of programmable epigenomic mRNA medicines. The company's OMEGA platform enables precise control of gene expression without altering native nucleic acid sequences, aiming to address the root causes of various diseases. Omega's therapeutic candidates target a range of conditions, including oncology, regenerative medicine, and multigenic and monogenic diseases. Founded in 2017 by Flagship Pioneering, Omega Therapeutics is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.